CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for TNF Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

TNF Pharmaceuticals Inc
1185 Avenue Of The Americas, Suite 249
Phone: (856) 848-8698p:856 848-8698 NEW YORK, NY  10036  United States Ticker: TNFATNFA
Business Summary
TNF Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel oral therapies for autoimmune and inflammatory conditions. It is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets: MYMD-1 and Supera-CBD. MYMD-1 is a clinical-stage small molecule that is being developed to treat age-related illnesses such as frailty and sarcopenia. MYMD-1 works by regulating the release of numerous pro-inflammatory cytokines, such as TNF-a, interleukin 6 (IL-6) and interleukin 17 (IL-17). MYMD-1 can also treat autoimmune diseases, including (but not limited to) multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. Supera-CBD is a synthetic analog of cannabidiol (CBD) being developed to treat various conditions, including, but not limited to, epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, and a monoamine oxidase enzyme (MAO) type B.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Joshua N.Silverman 54 1/1/2021 9/6/2018
President, Director, Chief Medical Officer MitchellGlass 58 6/13/2024 6/13/2024
Interim Chief Financial Officer IanRhodes 52 2/1/2021 2/1/2021
5 additional Officers and Directors records available in full report.

Business Names
Business Name
AKBS
AKER
Akers Acquisition Sub, Inc.
5 additional Business Names available in full report.

General Information
Number of Employees: 2 (As of 12/31/2024)
Outstanding Shares: 10,132,619 (As of 4/4/2025)
Shareholders: 735
Stock Exchange: NASD
Fax Number: (302) 655-5049


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 16, 2025